Ticker brief
RHHBY ROCHE HOLDINGS LTD-SPONS ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$55.19
1 day
-2.1%
14 days
+1.2%
mkt cap
·
signals 14d
18
authors 14d
10
crowd 14d
+1.1σ
Sentiment — last 14 days
daily mean sentiment, 2026-08-19 → 2026-08-28 · now +0.35 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 3 | +0.15 |
| @fwpharma | B | +0.98 | 3 | +0.13 |
| @CrweWorld | C | · | 3 | +0.38 |
| @bioinvestor24 | A | -0.45 | 2 | +0.25 |
| @ResearchPulse1 | B | +1.48 | 2 | +0.00 |
| @HunterAllen4 | C | -1.66 | 1 | +0.05 |
| @WSJ | A | -0.32 | 1 | +0.50 |
| @Biotech2k1 | A | +1.02 | 1 | +0.10 |
| @StockWorthyApp | C | +0.41 | 1 | +0.00 |
| @OzmosiHealth | C | · | 1 | +0.45 |
Recent signals18of 18 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @fwpharma | +0.25 | Roche signs an antibody-drug-conjugate deal with DualityBio worth more than 1B. | — | tweet ↗ |
| 2026-08-28 | @OzmosiHealth | +0.45 | Roche reports sustained two-year Vabysmo results in difficult-to-treat nAMD. | — | tweet ↗ |
| 2026-08-28 | @CrweWorld | +0.35 | Roche reports sustained two-year Vabysmo results in difficult-to-treat nAMD. | — | tweet ↗ |
| 2026-08-26 | @StockWorthyApp | +0.00 | Reports VEA's largest holdings and portfolio weights. | -3.0% | tweet ↗ |
| 2026-08-26 | @CrweWorld | +0.50 | Roche received FDA approval for companion diagnostic tests. | -3.0% | tweet ↗ |
| 2026-08-25 | @ResearchPulse1 | +0.10 | Gubra receives a $50M ABBV milestone as ABBV-295 enters Phase II obesity testing. | -5.6% | tweet ↗ |
| 2026-08-25 | @Biotech2k1 | +0.10 | Notes two companies are commercial and three peers have late-stage or approval-pending products. | -5.6% | tweet ↗ |
| 2026-08-24 | @bioinvestor24 | +0.20 | Compares obesity strategies, praising Roche investment but flagging tolerability risks | -4.0% | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | +0.25 | Dense biotech news list covering approvals, FDA actions, dosing and a reverse split. | -4.0% | tweet ↗ |
| 2026-08-24 | @fwpharma | -0.10 | Roche is making a $2.3B deal for Hanmi's muscle-sparing obesity asset. | -4.0% | tweet ↗ |
| 2026-08-24 | @WSJ | +0.50 | FDA cleared an Alzheimer's blood test developed by Roche and Eli Lilly. | -4.0% | tweet ↗ |
| 2026-08-24 | @CrweWorld | +0.30 | Hanmi signs an exclusive obesity-therapy licensing agreement with Genentech | -4.0% | tweet ↗ |
| 2026-08-24 | @ResearchPulse1 | -0.10 | Roche signed a $2.3 billion obesity-drug deal, with the author seeing positive read-through for Gubra. | -4.0% | tweet ↗ |
| 2026-08-21 | @BiopharmIQ | +0.10 | Lists opening biotech stock moves and the company events associated with them. | -5.0% | tweet ↗ |
| 2026-08-21 | @HunterAllen4 | +0.05 | Builds a long-horizon ONCY platform thesis from mechanistic, clinical and regulatory evidence. | -5.0% | tweet ↗ |
| 2026-08-20 | @fwpharma | +0.25 | Roche announced a $750 million Oregon manufacturing expansion. | -3.6% | tweet ↗ |
| 2026-08-19 | @bioinvestor24 | +0.30 | Frames personalized mRNA cancer vaccines as a massive opportunity for large pharma. | -5.2% | tweet ↗ |
| 2026-08-19 | @BiopharmIQ | +0.10 | Lists opening biotech movers and their associated trial, offering, facility and collaboration catalysts | -5.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.